JP2007517006A - Ｔｉｅ２（ｔｅｋ）活性のあるピリミジン - Google Patents

Ｔｉｅ２（ｔｅｋ）活性のあるピリミジン Download PDF

Info

Publication number
JP2007517006A
JP2007517006A JP2006546305A JP2006546305A JP2007517006A JP 2007517006 A JP2007517006 A JP 2007517006A JP 2006546305 A JP2006546305 A JP 2006546305A JP 2006546305 A JP2006546305 A JP 2006546305A JP 2007517006 A JP2007517006 A JP 2007517006A
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
amino
saturated
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006546305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517006A5 (enExample
Inventor
ジョーンズ，クリフォード・デービッド
ルーク，リチャード・ウィリアム・アーサー
マッコウル，ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0330001A external-priority patent/GB0330001D0/en
Priority claimed from GB0416850A external-priority patent/GB0416850D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2007517006A publication Critical patent/JP2007517006A/ja
Publication of JP2007517006A5 publication Critical patent/JP2007517006A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2006546305A 2003-12-24 2004-12-20 Ｔｉｅ２（ｔｅｋ）活性のあるピリミジン Pending JP2007517006A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0330001A GB0330001D0 (en) 2003-12-24 2003-12-24 Compounds
GB0416850A GB0416850D0 (en) 2004-07-29 2004-07-29 Compounds
PCT/GB2004/005332 WO2005060969A1 (en) 2003-12-24 2004-12-20 Pyrimidines with tie2 (tek) activity

Publications (2)

Publication Number Publication Date
JP2007517006A true JP2007517006A (ja) 2007-06-28
JP2007517006A5 JP2007517006A5 (enExample) 2008-02-07

Family

ID=34712716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006546305A Pending JP2007517006A (ja) 2003-12-24 2004-12-20 Ｔｉｅ２（ｔｅｋ）活性のあるピリミジン

Country Status (10)

Country Link
US (1) US20080027076A1 (enExample)
EP (1) EP1737462B1 (enExample)
JP (1) JP2007517006A (enExample)
AR (1) AR046996A1 (enExample)
AT (1) ATE402705T1 (enExample)
DE (1) DE602004015509D1 (enExample)
ES (1) ES2309591T3 (enExample)
TW (1) TW200524607A (enExample)
UY (1) UY28700A1 (enExample)
WO (1) WO2005060969A1 (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506365A (ja) * 2007-12-11 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト アルキニルアリール化合物およびその塩、それらを含む医薬組成物、その製造方法並びにその使用
JP2013064004A (ja) * 2005-12-23 2013-04-11 Ariad Pharmaceuticals Inc 二環式ヘテロアリール化合物
JP2013518078A (ja) * 2010-01-26 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ５−アルキニルピリミジン及びそれらのキナーゼ阻害剤としての使用
JP2017520607A (ja) * 2014-07-17 2017-07-27 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換尿素誘導体及びその薬学的使用
JP2019519595A (ja) * 2016-06-20 2019-07-11 テグ−キョンプク メディカル イノベーション ファウンデーション 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物
JP2020526550A (ja) * 2017-07-13 2020-08-31 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換尿素誘導体の塩及び薬におけるその使用
JP2023516159A (ja) * 2020-02-28 2023-04-18 テグ－キョンプク メディカル イノベーション ファウンデーション ３－（（８－（（１Ｈ－ピラゾール－４－イル）アミノ）イミダゾ［１，２－ａ］ピリジン－３－イル）エチニル）－Ｎ－フェニルベンズアミド誘導体、その調製法、それを活性成分として含有する癌の予防用又は治療用医薬組成物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410913B (de) * 2001-08-14 2003-08-25 Schelling Anlagenbau Gmbh Auflagetisch für eine trennsäge mit einem maschinentisch
DE602004018193D1 (de) * 2003-12-24 2009-01-15 Astrazeneca Ab Pyrimidine mit tie2 (tek) aktivität
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
WO2006082373A1 (en) * 2005-02-01 2006-08-10 Astrazeneca Ab Pyrimidine compounds having ties (tek) inhibitory activity
JP2008528662A (ja) * 2005-02-01 2008-07-31 アストラゼネカ アクチボラグ Ｔｉｅ２（ＴＥＫ）阻害活性を有するピリミジン化合物
GB0502418D0 (en) * 2005-02-05 2005-03-16 Astrazeneca Ab Compounds
WO2006103449A2 (en) * 2005-03-31 2006-10-05 Astrazeneca Ab Saminopyrimidine derivates with tie2 inhibiting activity
CN101389338B (zh) * 2005-12-23 2013-06-26 阿里亚德医药股份有限公司 双环杂芳基化合物
AU2013201242B2 (en) * 2005-12-23 2015-05-07 Takeda Pharmaceuticals U.S.A., Inc. Bicyclic heteroaryl compounds
AU2015210454B2 (en) * 2005-12-23 2016-10-27 Takeda Pharmaceuticals U.S.A., Inc. Bicyclic heteroaryl compounds
AU2007249924B2 (en) 2006-05-08 2013-07-04 Ariad Pharmaceuticals, Inc. Acetylenic heteroaryl compounds
EA200870515A1 (ru) * 2006-05-08 2009-06-30 Ариад Фармасьютикалз, Инк. Моноциклические гетероарильные соединения
EP2022785A1 (en) * 2007-06-20 2009-02-11 Bayer Schering Pharma Aktiengesellschaft Alkynylpyrimidines as Tie2 kinase inhibitors
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2323992B1 (en) 2008-07-29 2016-07-20 Boehringer Ingelheim International GmbH 5-alkynyl-pyrimidines
US8846664B2 (en) 2008-11-12 2014-09-30 Ariad Pharmaceuticals, Inc. Pyrazinopyrazines and derivatives as kinase inhibitors
US8633183B2 (en) 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
CA3022250A1 (en) 2012-12-12 2014-06-12 Ariad Pharmaceuticals, Inc. Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride
US20210284647A1 (en) * 2018-07-10 2021-09-16 Voronoibio Inc. N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1h-pyrazole-1-carboxamide derivative, and pharmaceutical composition containing same as active ingredient for treating kinase-related diseases
CN110272426B (zh) 2018-07-17 2022-05-31 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008205A1 (en) * 2000-07-24 2002-01-31 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2398274C (en) * 2000-02-25 2009-09-22 F. Hoffmann-La Roche Ag Adenosine receptor modulators
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002008205A1 (en) * 2000-07-24 2002-01-31 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013064004A (ja) * 2005-12-23 2013-04-11 Ariad Pharmaceuticals Inc 二環式ヘテロアリール化合物
JP2011506365A (ja) * 2007-12-11 2011-03-03 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト アルキニルアリール化合物およびその塩、それらを含む医薬組成物、その製造方法並びにその使用
JP2013518078A (ja) * 2010-01-26 2013-05-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ５−アルキニルピリミジン及びそれらのキナーゼ阻害剤としての使用
JP2017520607A (ja) * 2014-07-17 2017-07-27 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換尿素誘導体及びその薬学的使用
JP2019519595A (ja) * 2016-06-20 2019-07-11 テグ−キョンプク メディカル イノベーション ファウンデーション 新規のイミダゾピリジン誘導体、その製造方法及びこれを有効成分として含有する癌の予防又は治療用医薬組成物
JP2020526550A (ja) * 2017-07-13 2020-08-31 ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド 置換尿素誘導体の塩及び薬におけるその使用
JP7202350B2 (ja) 2017-07-13 2023-01-11 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換尿素誘導体の塩及び薬におけるその使用
JP2023516159A (ja) * 2020-02-28 2023-04-18 テグ－キョンプク メディカル イノベーション ファウンデーション ３－（（８－（（１Ｈ－ピラゾール－４－イル）アミノ）イミダゾ［１，２－ａ］ピリジン－３－イル）エチニル）－Ｎ－フェニルベンズアミド誘導体、その調製法、それを活性成分として含有する癌の予防用又は治療用医薬組成物
JP7505719B2 (ja) 2020-02-28 2024-06-25 テグ－キョンプク メディカル イノベーション ファウンデーション ３－（（８－（（１Ｈ－ピラゾール－４－イル）アミノ）イミダゾ［１，２－ａ］ピリジン－３－イル）エチニル）－Ｎ－フェニルベンズアミド誘導体、その調製法、それを活性成分として含有する癌の予防用又は治療用医薬組成物

Also Published As

Publication number Publication date
ES2309591T3 (es) 2008-12-16
EP1737462B1 (en) 2008-07-30
WO2005060969A1 (en) 2005-07-07
ATE402705T1 (de) 2008-08-15
DE602004015509D1 (de) 2008-09-11
EP1737462A1 (en) 2007-01-03
HK1102045A1 (en) 2007-11-02
UY28700A1 (es) 2005-07-29
AR046996A1 (es) 2006-01-04
TW200524607A (en) 2005-08-01
US20080027076A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
EP1737462B1 (en) Pyrimidines with tie2 (tek) activity
US20080194552A1 (en) Aminopyrimidine Derivatives With Tie2 Inhibiting Activity
US20080153838A1 (en) Compounds Having Tie2 (Tek) Activity
AU2007287428B2 (en) Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
EP1737463B1 (en) Pyrimidines with tie2 (tek) activity
KR20080083188A (ko) 모르폴리노 피리미딘 유도체 및 요법에서의 그 유도체의용도
US20080146599A1 (en) Pyrimidine Compounds Having Tie-2 (Tek) Inhibitory Activity
EP1575963B1 (en) Anti-angiogenetic therapeutic agents
JP2008528663A (ja) Ｔｉｅｓ（ＴＥＫ）阻害活性を有するピリミジン化合物
ES2393215T3 (es) Derivados de morfolino pirimidina útiles en el tratamiento de trastornos proliferativos
JP2007520536A (ja) Ｔｉｅ２の阻害剤としての置換チエノ及びチアゾロ−［２，３−ｄ］ピリミジン及び［２，３−ｃ］ピリジン
CN101151261A (zh) 具有tie2（tek）抑制活性的嘧啶化合物
HK1102045B (en) Pyrimidines with tie2 (tek) activity
CN101137652A (zh) 具有tie2（tek）抑制活性的嘧啶化合物
HK1102425B (en) Pyrimidines with tie2 (tek) activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111122